Key Points
- Bernadette Connaughton, a Halozyme director, sold 2,000 shares on Jan. 5 at an average price of $70.25 for $140,500, leaving her with 40,123 shares (a 4.75% reduction in her position).
- Halozyme beat recent quarterly estimates, reporting $1.72 EPS versus $1.63 expected and $354.3M revenue (up 22.1% YoY); the stock has a market cap of $8.6B and a P/E of 15.4 with a 1‑year range of $47.50–$79.50.
- Analyst coverage is mixed with a consensus "Hold" and an average target of $75.10 (7 Buys, 6 Holds, 1 Sell), and institutional investors own about 97.79% of the shares.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 2,000 shares of the company's stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Bernadette Connaughton also recently made the following trade(s):
- On Monday, December 1st, Bernadette Connaughton sold 829 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.60, for a total transaction of $59,356.40.
- On Monday, November 10th, Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $68.48, for a total transaction of $136,960.00.
Halozyme Therapeutics Price Performance
Shares of NASDAQ:HALO opened at $73.13 on Wednesday. The firm has a market cap of $8.60 billion, a price-to-earnings ratio of 15.40, a P/E/G ratio of 0.32 and a beta of 0.94. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $79.50. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The business has a fifty day simple moving average of $67.79 and a 200 day simple moving average of $66.35.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same period in the prior year, the firm posted $1.27 EPS. The business's revenue was up 22.1% compared to the same quarter last year. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have commented on HALO. HC Wainwright reissued a "buy" rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Friday, December 19th. Benchmark upped their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an "overweight" rating on the stock in a research report on Monday, October 20th. Leerink Partnrs raised Halozyme Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, October 14th. Finally, Zacks Research downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 6th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Hold" and a consensus price target of $75.10.
View Our Latest Research Report on HALO
Institutional Trading of Halozyme Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Campbell Newman Asset Management Inc. increased its stake in Halozyme Therapeutics by 0.4% during the third quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company's stock valued at $2,705,000 after acquiring an additional 153 shares during the period. Coldstream Capital Management Inc. boosted its stake in Halozyme Therapeutics by 1.9% in the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company's stock valued at $654,000 after buying an additional 165 shares in the last quarter. Alps Advisors Inc. grew its position in Halozyme Therapeutics by 3.0% in the third quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company's stock valued at $435,000 after acquiring an additional 170 shares during the period. EverSource Wealth Advisors LLC grew its position in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock valued at $140,000 after acquiring an additional 174 shares during the period. Finally, Private Advisor Group LLC raised its stake in Halozyme Therapeutics by 0.8% during the third quarter. Private Advisor Group LLC now owns 23,623 shares of the biopharmaceutical company's stock worth $1,733,000 after acquiring an additional 184 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.
Halozyme Therapeutics Company Profile
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
